About Zogenix (NASDAQ:ZGNX)
Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. ZX008 has received orphan drug designation in the United States and European Union (EU), for the treatment of Dravet syndrome. The Company has an additional product candidate, Relday (risperidone once-monthly long-acting injectable) for the treatment of schizophrenia. Relday is a long-acting injectable formulation of risperidone. Risperidone is used to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. It has completed the Phase I program for Relday.
Industry, Sector and Symbol
Industry Bio Medical Devices
Trailing P/E Ratio-9.33257918552036
Forward P/E Ratio-9.27
Sales & Book Value
Annual Sales$28.85 million
Price / Sales48.97
Price / CashN/A
Book Value$4.87 per share
Price / Book8.47
Return on Equity-99.61%
Return on Assets-44.17%
Zogenix (NASDAQ:ZGNX) Frequently Asked Questions
What is Zogenix's stock symbol?
Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."
How were Zogenix's earnings last quarter?
Zogenix, Inc. (NASDAQ:ZGNX) posted its earnings results on Tuesday, August, 8th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. The company had revenue of $7.10 million for the quarter, compared to analysts' expectations of $3.48 million. Zogenix had a negative return on equity of 99.61% and a negative net margin of 309.76%. The firm's quarterly revenue was up 238.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.76) EPS. View Zogenix's Earnings History.
Where is Zogenix's stock going? Where will Zogenix's stock price be in 2018?
6 equities research analysts have issued 1-year price targets for Zogenix's shares. Their predictions range from $28.00 to $56.00. On average, they expect Zogenix's share price to reach $48.00 in the next twelve months. View Analyst Ratings for Zogenix.
What are Wall Street analysts saying about Zogenix stock?
Here are some recent quotes from research analysts about Zogenix stock:
- 1. Mizuho analysts commented, "We are encouraged by the company’s execution as well as solid clinical data from ZX008 in the previous Study 1 and see a high likelihood that the upcoming top- line data readouts will be favorable. We believe the readout is likely to take place in June 2018." (2/1/2018)
- 2. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel DosePro is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (1/27/2018)
Who are some of Zogenix's key competitors?
Some companies that are related to Zogenix include China Biologic Products (CBPO), Udg Healthcare (UDHCF), Evotec (EVTCY), Clovis Oncology (CLVS), National Vision (EYE), argenx SE - American Depositary Shares (ARGX), Puma Biotechnology (PBYI), Inogen (INGN), Emergent Biosolutions (EBS), Nevro (NVRO), Ironwood Pharmaceuticals (IRWD), Magellan Health (MGLN), Select Medical (SEM), Merit Medical Systems (MMSI), Ultragenyx Pharmaceutical (RARE), Halyard Health (HYH), Spectrum Pharmaceuticals (SPPI) and Wright Medical Group (WMGI).
Who are Zogenix's key executives?
Zogenix's management team includes the folowing people:
- Cam L. Garner, Independent Chairman of the Board (Age 67)
- Stephen J. Farr Ph.D., President, Chief Executive Officer, Director (Age 56)
- Michael P. Smith, Chief Financial Officer, Executive Vice President, Treasurer, Secretary (Age 48)
- Gail M. Farfel Ph.D., Executive Vice President, Chief Development Officer (Age 51)
- Bradley S. Galer M.D., Executive Vice President and Chief Medical Officer (Age 53)
- James B. Breitmeyer M.D., Ph.D., Director (Age 61)
- Roger L. Hawley, Director (Age 63)
- Erle T. Mast, Independent Director (Age 52)
- Mark C. Wiggins, Independent Director (Age 59)
Who owns Zogenix stock?
Zogenix's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (11.59%), BlackRock Inc. (7.76%), Goldman Sachs Group Inc. (3.54%), Deutsche Bank AG (3.03%), Eagle Asset Management Inc. (2.90%) and VHCP Management II LLC (2.49%). Company insiders that own Zogenix stock include Bradley S Galer, Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.
Who sold Zogenix stock? Who is selling Zogenix stock?
Zogenix's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ascend Capital LLC, Candriam Luxembourg S.C.A., Emory University, Gagnon Securities LLC, VHCP Management II LLC, EAM Investors LLC and Jane Street Group LLC. View Insider Buying and Selling for Zogenix.
Who bought Zogenix stock? Who is buying Zogenix stock?
Zogenix's stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., BlackRock Inc., Farallon Capital Management LLC, Deutsche Bank AG, Broadfin Capital LLC, Perceptive Advisors LLC and Goldman Sachs Group Inc.. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix.
How do I buy Zogenix stock?
Shares of Zogenix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zogenix's stock price today?
One share of Zogenix stock can currently be purchased for approximately $41.25.
How big of a company is Zogenix?
Zogenix has a market capitalization of $1.42 billion and generates $28.85 million in revenue each year. The company earns $-69,700,000.00 in net income (profit) each year or ($4.42) on an earnings per share basis. Zogenix employs 67 workers across the globe.
How can I contact Zogenix?
Zogenix's mailing address is 5858 HORTON STREET #455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]
MarketBeat Community Rating for Zogenix (ZGNX)MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Zogenix (NASDAQ:ZGNX) Earnings History and Estimates Chart
Zogenix (NASDAQ ZGNX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2 2017||($0.89)||($0.90)||$3.48 million||$7.10 million||View||Listen|
|5/4/2017||Q1 2017||($0.88)||($0.85)||$4.23 million||$2.70 million||View||Listen|
|3/9/2017||Q4 2016||($0.84)||($0.73)||$5.05 million||$10.99 million||View||N/A|
|11/7/2016||Q3||($0.96)||($0.69)||$3.10 million||$6.57 million||View||Listen|
|8/9/2016||Q216||($0.81)||($0.76)||$5.36 million||$2.10 million||View||N/A|
|5/10/2016||Q116||($0.62)||($0.42)||$4.90 million||$9.20 million||View||Listen|
|3/10/2016||Q415||($0.69)||($0.36)||$6.39 million||$6.10 million||View||Listen|
|11/9/2015||Q315||($0.74)||($0.65)||$5.90 million||$9.12 million||View||N/A|
|8/10/2015||Q215||($0.77)||$3.78||$5.13 million||$7.40 million||View||Listen|
|5/11/2015||Q115||($0.13)||($0.15)||$8.54 million||$4.60 million||View||Listen|
|3/10/2015||Q414||($0.11)||($0.13)||$11.50 million||$14.90 million||View||Listen|
|11/6/2014||Q314||($0.16)||($0.15)||$8.30 million||$8.80 million||View||Listen|
|8/5/2014||Q214||($0.16)||($0.19)||$9.84 million||$9.16 million||View||Listen|
|5/8/2014||Q114||($0.17)||($0.20)||$8.71 million||$7.70 million||View||Listen|
|3/5/2014||Q413||($0.09)||($0.13)||$8.68 million||$9.90 million||View||Listen|
|11/4/2013||Q313||($0.09)||($0.12)||$9.33 million||$7.20 million||View||N/A|
|8/8/2013||Q2 2013||($0.15)||($0.13)||$8.63 million||$8.90 million||View||Listen|
|5/9/2013||Q1 2013||($0.14)||($0.21)||$9.28 million||$7.00 million||View||Listen|
|3/15/2013||Q4 2012||($0.17)||($0.16)||$9.87 million||$9.50 million||View||Listen|
|11/8/2012||Q312||($0.16)||($0.16)||$9.98 million||$8.50 million||View||N/A|
Zogenix (NASDAQ:ZGNX) Earnings Estimates
2018 EPS Consensus Estimate: ($3.63)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Zogenix (NASDAQ:ZGNX)
No dividend announcements for this company have been tracked by MarketBeat.com
Zogenix (NASDAQ ZGNX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 73.47%
Zogenix (NASDAQ ZGNX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/13/2017||Bradley S. Galer||EVP||Buy||1,346||$36.59||$49,250.14|| |
|12/11/2017||Roger Hawley||Director||Sell||63,203||$36.84||$2,328,398.52||105,575|| |
|12/8/2017||Roger Hawley||Director||Sell||11,797||$37.02||$436,724.94||105,575|| |
|10/3/2017||Life Sciences Maste Perceptive||Major Shareholder||Buy||300,000||$37.50||$11,250,000.00|| |
|9/29/2017||Life Sciences Maste Perceptive||Major Shareholder||Buy||222,055||$32.83||$7,290,065.65|| |
|6/30/2017||Life Sciences Maste Perceptive||Major Shareholder||Buy||175,653||$14.45||$2,538,185.85|| |
|3/16/2017||Renee P Tannenbaum||Director||Buy||5,000||$11.00||$55,000.00||10,000|| |
|12/15/2015||Roger Hawley||Director||Buy||10,000||$13.74||$137,400.00||1,404,447|| |
|6/13/2014||Cam L Garner||Director||Buy||30,000||$1.66||$49,800.00|| |
|6/3/2014||Ann D Rhoads||CFO||Sell||19,229||$2.10||$40,380.90|| |
|6/3/2014||Roger Hawley||CEO||Sell||25,078||$2.10||$52,663.80|| |
|6/3/2014||Stephen J Farr||COO||Sell||20,900||$2.10||$43,890.00|| |
|11/20/2013||Richard Scott Shively||Insider||Buy||67,000||$2.79||$186,930.00||79,500|| |
|12/13/2012||Cynthia Y Robinson||Insider||Buy||50,000||$1.17||$58,500.00|| |
|12/12/2012||Ann D Rhoads||CFO||Buy||17,500||$1.19||$20,825.00|| |
|12/12/2012||Cam L Garner||Director||Buy||70,000||$1.21||$84,700.00|| |
|12/11/2012||Erle T Mast||Director||Buy||10,000||$1.15||$11,500.00|| |
Zogenix (NASDAQ ZGNX) News Headlines
|Zogenix (ZGNX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow|
seekingalpha.com - February 16 at 5:00 PM
|BidaskClub Upgrades Zogenix (ZGNX) to "Buy"|
www.americanbankingnews.com - February 10 at 7:24 AM
|Stock Traders Buy Large Volume of Call Options on Zogenix (ZGNX)|
www.americanbankingnews.com - February 9 at 1:10 AM
|Zogenix to Participate in Leerink Partners 7th Annual Global Healthcare Conference|
finance.yahoo.com - February 8 at 8:31 AM
|BRIEF-Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008|
www.reuters.com - February 6 at 4:01 PM
|Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome - GlobeNewswire (press release)|
globenewswire.com - February 6 at 9:32 AM
|Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome|
finance.yahoo.com - February 6 at 9:32 AM
|Zogenix (ZGNX) Stock Rating Upgraded by ValuEngine|
www.americanbankingnews.com - February 4 at 6:22 AM
|Zogenix, Inc. (ZGNX) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - February 4 at 5:30 AM
|BRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet Syndrome|
www.reuters.com - February 1 at 9:40 AM
|Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome|
finance.yahoo.com - February 1 at 9:40 AM
|Zogenix (ZGNX) Upgraded to "Hold" by Zacks Investment Research|
www.americanbankingnews.com - January 27 at 1:46 PM
|Zogenix Target of Unusually High Options Trading (ZGNX)|
www.americanbankingnews.com - January 22 at 1:28 AM
|Zogenix (ZGNX) Downgraded by BidaskClub|
www.americanbankingnews.com - January 12 at 12:40 AM
|Zogenix, Inc. (ZGNX) Given Consensus Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - January 10 at 5:38 AM
|Zogenix CEO explains company pivot from opioids to epilepsy drugs|
www.bizjournals.com - January 4 at 4:23 PM
|Commit To Purchase Zogenix At $23, Earn 19.6% Using Options|
www.nasdaq.com - December 30 at 10:14 AM
|Ganaxalone Faces Stiff Competition from Other Drugs under Development|
finance.yahoo.com - December 27 at 1:14 PM
|-$1.01 EPS Expected for Zogenix, Inc. (ZGNX) This Quarter|
www.americanbankingnews.com - December 23 at 1:24 AM
|BRIEF-Zogenix Says May Issue And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $75.0 Mln|
www.reuters.com - December 22 at 6:26 PM
|Zogenix, Inc. is trading above its 50 day moving average : ZGNX-US : December 20, 2017|
finance.yahoo.com - December 20 at 10:38 AM
|Zogenix, Inc. (ZGNX) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - December 16 at 5:42 AM
|Zogenix, Inc. (ZGNX) EVP Purchases $49,250.14 in Stock|
www.americanbankingnews.com - December 15 at 6:54 PM
|Zogenix, Inc. (ZGNX) Director Sells $436,724.94 in Stock|
www.americanbankingnews.com - December 11 at 8:53 PM
|Roger Hawley Sells 63,203 Shares of Zogenix, Inc. (ZGNX) Stock|
www.americanbankingnews.com - December 11 at 8:50 PM
|Zogenix (ZGNX) Earns Buy Rating from Mizuho|
www.americanbankingnews.com - December 7 at 8:34 AM
|Zogenix, Inc. – Value Analysis (NASDAQ:ZGNX) : December 6, 2017|
finance.yahoo.com - December 6 at 4:24 PM
|Zogenix, Inc. breached its 50 day moving average in a Bearish Manner : ZGNX-US : December 5, 2017|
finance.yahoo.com - December 5 at 12:19 PM
|Zogenix (ZGNX) Announces New Positive Efficacy, Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome at AES|
www.streetinsider.com - December 4 at 4:21 PM
|Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome|
finance.yahoo.com - December 4 at 10:37 AM
|Zogenix (ZGNX) Begins Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome|
www.streetinsider.com - November 30 at 11:14 AM
|Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome|
finance.yahoo.com - November 29 at 10:41 AM
|Zogenix to Participate in the Global Mizuho Investor Conference 2017|
feeds.benzinga.com - November 29 at 8:23 AM
|Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4|
finance.yahoo.com - November 28 at 11:38 AM
|As Zogenix Develops Its Seizure Treatment Pipeline, Analyst Predicts More Upside|
www.msn.com - November 27 at 3:35 PM
|JMP Securities Begins Coverage on Zogenix, Inc. (ZGNX)|
www.americanbankingnews.com - November 27 at 8:36 AM
|Zogenix (ZGNX) Announces New Data from Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at AES|
www.streetinsider.com - November 23 at 6:26 PM
|Zogenix (ZGNX) Announces New Data from Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on ... - StreetInsider.com|
www.streetinsider.com - November 23 at 8:26 AM
|Zogenix, Inc. (ZGNX) Given Average Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - November 21 at 5:56 AM
|Zacks: Analysts Expect Zogenix, Inc. (ZGNX) Will Post Earnings of -$1.01 Per Share|
www.americanbankingnews.com - November 16 at 5:30 PM
|Zogenix to Present at Stifel 2017 Healthcare Conference|
finance.yahoo.com - November 16 at 10:29 AM
|FY2017 EPS Estimates for Zogenix, Inc. (ZGNX) Lowered by Analyst|
www.americanbankingnews.com - November 10 at 12:26 PM
|FY2017 EPS Estimates for Zogenix, Inc. Decreased by Analyst (ZGNX)|
www.americanbankingnews.com - November 10 at 12:26 PM
|Research Analysts Offer Predictions for Zogenix, Inc.'s Q2 2018 Earnings (ZGNX)|
www.americanbankingnews.com - November 9 at 12:34 PM
|Edited Transcript of ZGNX earnings conference call or presentation 7-Nov-17 9:30pm GMT|
finance.yahoo.com - November 9 at 10:49 AM
|Mizuho Reiterates Buy Rating for Zogenix, Inc. (ZGNX)|
www.americanbankingnews.com - November 8 at 10:26 PM
|Zogenix's (ZGNX) CEO Stephen Farr on Q3 2017 Results - Earnings Call Transcript|
seekingalpha.com - November 8 at 2:25 AM
|Zogenix reports 3Q loss|
finance.yahoo.com - November 7 at 9:24 PM
|Zogenix, Inc. to Host Earnings Call|
finance.yahoo.com - November 7 at 4:19 PM
|Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 7 at 4:19 PM
Zogenix (NASDAQ:ZGNX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Zogenix (NASDAQ:ZGNX) Income Statement, Balance Sheet and Cash Flow Statement
Zogenix (NASDAQ ZGNX) Stock Chart for Saturday, February, 17, 2018